Zimmer Biomet Q2 FY26 EPS rises 33.8% to $1.03; net sales increase 4.8% to $2.18 billion vs year ago

Zimmer Biomet posted Q2 net sales of $2.18 billion, up 4.8% from a year earlier.

Net earnings rose to $198.3 million; GAAP diluted EPS climbed 33.8% to $1.03.

Operating cash flow totaled $447.9 million, producing free cash flow of $308.3 million.

The company raised its 2026 outlook for reported revenue growth to 3.9%–4.9% from 2.5%–4.5% and lifted adjusted diluted EPS to $8.47–$8.59.

It also boosted 2026 share repurchase expectations to as much as $1 billion. CEO Ivan Tornos cited strong first-half results and momentum from innovation.